ID   LOXL2_HUMAN             Reviewed;         774 AA.
AC   Q9Y4K0; B2R5Q0; Q53HV3; Q9BW70; Q9Y5Y8;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 157.
DE   RecName: Full=Lysyl oxidase homolog 2;
DE            EC=1.4.3.13 {ECO:0000269|PubMed:20306300, ECO:0000269|PubMed:20439985, ECO:0000269|PubMed:23319596};
DE   AltName: Full=Lysyl oxidase-like protein 2;
DE   AltName: Full=Lysyl oxidase-related protein 2;
DE   AltName: Full=Lysyl oxidase-related protein WS9-14;
DE   Flags: Precursor;
GN   Name=LOXL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9079631; DOI=10.1074/jbc.272.13.8157;
RA   Saito H., Papaconstantinou J., Sato H., Goldstein S.;
RT   "Regulation of a novel gene encoding a lysyl oxidase-related protein
RT   in cellular adhesion and senescence.";
RL   J. Biol. Chem. 272:8157-8160(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-570.
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-570.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 202-774.
RC   TISSUE=Placenta, and Spleen;
RX   PubMed=10212285; DOI=10.1074/jbc.274.18.12939;
RA   Jourdan-Le Saux C., Tronecker H., Bogic L., Bryant-Greenwood G.D.,
RA   Boyd C.D., Csiszar K.;
RT   "The LOXL2 gene encodes a new lysyl oxidase-like protein and is
RT   expressed at high levels in reproductive tissues.";
RL   J. Biol. Chem. 274:12939-12944(1999).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=16096638; DOI=10.1038/sj.emboj.7600781;
RA   Peinado H., Del Carmen Iglesias-de la Cruz M., Olmeda D., Csiszar K.,
RA   Fong K.S., Vega S., Nieto M.A., Cano A., Portillo F.;
RT   "A molecular role for lysyl oxidase-like 2 enzyme in snail regulation
RT   and tumor progression.";
RL   EMBO J. 24:3446-3458(2005).
RN   [8]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=20026874; DOI=10.1074/jbc.M109.042424;
RA   Schietke R., Warnecke C., Wacker I., Schodel J., Mole D.R.,
RA   Campean V., Amann K., Goppelt-Struebe M., Behrens J., Eckardt K.U.,
RA   Wiesener M.S.;
RT   "The lysyl oxidases LOX and LOXL2 are necessary and sufficient to
RT   repress E-cadherin in hypoxia: insights into cellular transformation
RT   processes mediated by HIF-1.";
RL   J. Biol. Chem. 285:6658-6669(2010).
RN   [9]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME
RP   REGULATION.
RX   PubMed=20439985; DOI=10.1074/jbc.M109.094136;
RA   Rodriguez H.M., Vaysberg M., Mikels A., McCauley S., Velayo A.C.,
RA   Garcia C., Smith V.;
RT   "Modulation of lysyl oxidase-like 2 enzymatic activity by an
RT   allosteric antibody inhibitor.";
RL   J. Biol. Chem. 285:20964-20974(2010).
RN   [10]
RP   ENZYME REGULATION.
RX   PubMed=20818376; DOI=10.1038/nm.2208;
RA   Barry-Hamilton V., Spangler R., Marshall D., McCauley S.,
RA   Rodriguez H.M., Oyasu M., Mikels A., Vaysberg M., Ghermazien H.,
RA   Wai C., Garcia C.A., Velayo A.C., Jorgensen B., Biermann D., Tsai D.,
RA   Green J., Zaffryar-Eilot S., Holzer A., Ogg S., Thai D., Neufeld G.,
RA   Van Vlasselaer P., Smith V.;
RT   "Allosteric inhibition of lysyl oxidase-like-2 impedes the development
RT   of a pathologic microenvironment.";
RL   Nat. Med. 16:1009-1017(2010).
RN   [11]
RP   FUNCTION.
RX   PubMed=21835952; DOI=10.1182/blood-2010-10-313296;
RA   Bignon M., Pichol-Thievend C., Hardouin J., Malbouyres M., Brechot N.,
RA   Nasciutti L., Barret A., Teillon J., Guillon E., Etienne E., Caron M.,
RA   Joubert-Caron R., Monnot C., Ruggiero F., Muller L., Germain S.;
RT   "Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and
RT   type IV collagen assembly in the endothelial basement membrane.";
RL   Blood 118:3979-3989(2011).
RN   [12]
RP   ROLE IN TUMOR PROGRESSION.
RX   PubMed=21233336; DOI=10.1158/0008-5472.CAN-10-2868;
RA   Barker H.E., Chang J., Cox T.R., Lang G., Bird D., Nicolau M.,
RA   Evans H.R., Gartland A., Erler J.T.;
RT   "LOXL2-mediated matrix remodeling in metastasis and mammary gland
RT   involution.";
RL   Cancer Res. 71:1561-1572(2011).
RN   [13]
RP   ROLE IN TUMOR PROGRESSION.
RX   PubMed=21732535; DOI=10.1002/emmm.201100156;
RA   Moreno-Bueno G., Salvador F., Martin A., Floristan A., Cuevas E.P.,
RA   Santos V., Montes A., Morales S., Castilla M.A., Rojo-Sebastian A.,
RA   Martinez A., Hardisson D., Csiszar K., Portillo F., Peinado H.,
RA   Palacios J., Cano A.;
RT   "Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity
RT   required for metastatic dissemination of basal-like breast
RT   carcinomas.";
RL   EMBO Mol. Med. 3:528-544(2011).
RN   [14]
RP   CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20306300; DOI=10.1007/s11033-010-0088-0;
RA   Kim Y.M., Kim E.C., Kim Y.;
RT   "The human lysyl oxidase-like 2 protein functions as an amine oxidase
RT   toward collagen and elastin.";
RL   Mol. Biol. Rep. 38:145-149(2011).
RN   [15]
RP   MUTAGENESIS OF TYR-689.
RX   PubMed=22157764; DOI=10.1074/jbc.M111.261016;
RA   Lugassy J., Zaffryar-Eilot S., Soueid S., Mordoviz A., Smith V.,
RA   Kessler O., Neufeld G.;
RT   "The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required
RT   for LOXL2-induced inhibition of keratinocyte differentiation.";
RL   J. Biol. Chem. 287:3541-3549(2012).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 626-HIS--HIS-628.
RX   PubMed=22483618; DOI=10.1016/j.molcel.2012.03.002;
RA   Herranz N., Dave N., Millanes-Romero A., Morey L., Diaz V.M.,
RA   Lorenz-Fonfria V., Gutierrez-Gallego R., Jeronimo C., Di Croce L.,
RA   Garcia de Herreros A., Peiro S.;
RT   "Lysyl oxidase-like 2 deaminates lysine 4 in histone H3.";
RL   Mol. Cell 46:369-376(2012).
RN   [17]
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   GLYCOSYLATION AT ASN-455 AND ASN-644, MUTAGENESIS OF ASN-455 AND
RP   ASN-644, CROSS-LINK FORMATION, AND SUBCELLULAR LOCATION.
RX   PubMed=23319596; DOI=10.1074/jbc.C112.421768;
RA   Xu L., Go E.P., Finney J., Moon H., Lantz M., Rebecchi K., Desaire H.,
RA   Mure M.;
RT   "Post-translational Modifications of Recombinant Human Lysyl Oxidase-
RT   like 2 (rhLOXL2) Secreted from Drosophila S2 Cells.";
RL   J. Biol. Chem. 288:5357-5363(2013).
CC   -!- FUNCTION: Mediates the post-translational oxidative deamination of
CC       lysine residues on target proteins leading to the formation of
CC       deaminated lysine (allysine). When secreted in extracellular
CC       matrix, promotes cross-linking of extracellular matrix proteins by
CC       mediating oxidative deamination of peptidyl lysine residues in
CC       precursors to fibrous collagen and elastin. Acts as a regulator of
CC       sprouting angiogenesis, probably via collagen IV scaffolding. When
CC       nuclear, acts as a transcription corepressor and specifically
CC       mediates deamination of trimethylated 'Lys-4' of histone H3
CC       (H3K4me3), a specific tag for epigenetic transcriptional
CC       activation. Involved in epithelial to mesenchymal transition (EMT)
CC       via interaction with SNAI1 and participates in repression of E-
CC       cadherin, probably by mediating deamination of histone H3. Also
CC       involved in E-cadherin repression following hypoxia, a hallmark of
CC       epithelial to mesenchymal transition believed to amplify tumor
CC       aggressiveness, suggesting that it may play a role in tumor
CC       progression. Acts as a regulator of chondrocyte differentiation,
CC       probably by regulating expression of factors that control
CC       chondrocyte differentiation. {ECO:0000269|PubMed:16096638,
CC       ECO:0000269|PubMed:20026874, ECO:0000269|PubMed:21233336,
CC       ECO:0000269|PubMed:21732535, ECO:0000269|PubMed:21835952,
CC       ECO:0000269|PubMed:22483618}.
CC   -!- CATALYTIC ACTIVITY: [Protein]-L-lysine + O(2) + H(2)O = [protein]-
CC       (S)-2-amino-6-oxohexanoate + NH(3) + H(2)O(2).
CC       {ECO:0000269|PubMed:20306300, ECO:0000269|PubMed:20439985,
CC       ECO:0000269|PubMed:23319596}.
CC   -!- COFACTOR:
CC       Name=Cu cation; Xref=ChEBI:CHEBI:23378;
CC         Evidence={ECO:0000250|UniProtKB:P16636};
CC   -!- COFACTOR:
CC       Name=lysine tyrosylquinone residue; Xref=ChEBI:CHEBI:20489;
CC         Evidence={ECO:0000250|UniProtKB:P33072};
CC       Note=Contains 1 lysine tyrosylquinone.
CC       {ECO:0000250|UniProtKB:P33072};
CC   -!- ENZYME REGULATION: According to some reports, it is inhibited by
CC       beta-aminopropionitrile (BAPN) (PubMed:20439985 and
CC       PubMed:23319596). According to another report, it is not inhibited
CC       by beta-aminopropionitrile (BAPN) (PubMed:20306300). Specifically
CC       inhibited by a mouse monoclonal antibody AB0023, inhibition occurs
CC       in a non-competitive manner. {ECO:0000269|PubMed:20306300,
CC       ECO:0000269|PubMed:20439985, ECO:0000269|PubMed:20818376,
CC       ECO:0000269|PubMed:23319596}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.01 mM for 1,5-diaminopentane {ECO:0000269|PubMed:20439985,
CC         ECO:0000269|PubMed:23319596};
CC         KM=1.05 mM for spermine {ECO:0000269|PubMed:20439985,
CC         ECO:0000269|PubMed:23319596};
CC         KM=0.59 uM for tropoelastin (without the first three SRCR
CC         domains) {ECO:0000269|PubMed:20439985,
CC         ECO:0000269|PubMed:23319596};
CC         KM=0.62 uM for tropoelastin (without all four SRCR domains)
CC         {ECO:0000269|PubMed:20439985, ECO:0000269|PubMed:23319596};
CC         Note=kcat is 2.04 min(-1) with tropoelastin as substrate
CC         (without the first three SRCR domains). kcat is 0.62 min(-1)
CC         with tropoelastin as substrate (without all four SRCR domains).;
CC   -!- SUBUNIT: Component of some chromatin repressor complex. Interacts
CC       with SNAI1. {ECO:0000269|PubMed:16096638}.
CC   -!- INTERACTION:
CC       Q15910:EZH2; NbExp=2; IntAct=EBI-7172227, EBI-530054;
CC       Q13547:HDAC1; NbExp=2; IntAct=EBI-7172227, EBI-301834;
CC       P49006:MARCKSL1; NbExp=4; IntAct=EBI-7172227, EBI-4289961;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-7172227, EBI-347218;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix, basement membrane {ECO:0000269|PubMed:23319596}. Nucleus
CC       {ECO:0000269|PubMed:22483618}. Chromosome
CC       {ECO:0000269|PubMed:22483618}. Note=Associated with chromatin
CC       (PubMed:22483618). It is unclear how LOXL2 is nuclear: it contains
CC       a clear signal sequence and is predicted to localize in the
CC       extracellular medium (PubMed:22483618). However, different reports
CC       confirmed the intracellular location and its key role in
CC       transcription regulation (PubMed:22483618).
CC       {ECO:0000269|PubMed:22483618}.
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues. Highest expression
CC       in reproductive tissues, placenta, uterus and prostate. Up-
CC       regulated in a number of cancers cells and tissues.
CC   -!- INDUCTION: Strongly induced in hypoxia. Direct transcriptional
CC       target of HIF1A. {ECO:0000269|PubMed:20026874}.
CC   -!- DOMAIN: The fourth SRCR domain plays a important role in
CC       optimizing the catalytic activity of the lysyl-oxidase like (LOX)
CC       catalytic domain.
CC   -!- PTM: The lysine tyrosylquinone cross-link (LTQ) is generated by
CC       condensation of the epsilon-amino group of a lysine with a
CC       topaquinone produced by oxidation of tyrosine.
CC       {ECO:0000269|PubMed:23319596}.
CC   -!- PTM: N-glycosylated. N-glycosylation on Asn-455 and Asn-644 may be
CC       essential for proper folding and secretion; may be composed of a
CC       fucosylated carbohydrates attached to a trimannose N-linked glycan
CC       core. {ECO:0000269|PubMed:23319596}.
CC   -!- MISCELLANEOUS: Its overexpression in a number of cancer and its
CC       ability to promote epithelial to mesenchymal transition suggest
CC       that LOXL2 might play a role in tumor progression: expression is
CC       correlated with metastasis and decreased survival in patients with
CC       aggressive breast cancer (PubMed:21732535). Allosteric inhibition
CC       by AB0023 inhibits formation of the tumor microenvironment and
CC       reduces metastatic tumor burden in xenograft models
CC       (PubMed:20818376 and PubMed:21732535). However, inhibiting the
CC       enzyme activity of LOXL2 may not be sufficient, since mutants that
CC       lack enzyme activity or inhibition of the activity by AB0023
CC       antibody does not prevent inhibition of the differentiation of
CC       keratinocytes, thereby promoting development of squamous cell
CC       carcinomas (PubMed:22157764). {ECO:0000305|PubMed:21732535,
CC       ECO:0000305|PubMed:22157764}.
CC   -!- SIMILARITY: Belongs to the lysyl oxidase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD34343.1; Type=Erroneous termination; Positions=775; Note=Translated as stop.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LOXL2ID41192ch8p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U89942; AAB49697.1; -; mRNA.
DR   EMBL; AK312266; BAG35197.1; -; mRNA.
DR   EMBL; AK222477; BAD96197.1; -; mRNA.
DR   EMBL; AC090197; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000594; AAH00594.1; -; mRNA.
DR   EMBL; AF117949; AAD34343.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS34864.1; -.
DR   RefSeq; NP_002309.1; NM_002318.2.
DR   UniGene; Hs.626637; -.
DR   ProteinModelPortal; Q9Y4K0; -.
DR   SMR; Q9Y4K0; -.
DR   BioGrid; 110201; 30.
DR   IntAct; Q9Y4K0; 12.
DR   MINT; MINT-4053647; -.
DR   STRING; 9606.ENSP00000373783; -.
DR   GuidetoPHARMACOLOGY; 2853; -.
DR   iPTMnet; Q9Y4K0; -.
DR   PhosphoSitePlus; Q9Y4K0; -.
DR   BioMuta; LOXL2; -.
DR   DMDM; 13878585; -.
DR   EPD; Q9Y4K0; -.
DR   MaxQB; Q9Y4K0; -.
DR   PaxDb; Q9Y4K0; -.
DR   PeptideAtlas; Q9Y4K0; -.
DR   PRIDE; Q9Y4K0; -.
DR   DNASU; 4017; -.
DR   Ensembl; ENST00000389131; ENSP00000373783; ENSG00000134013.
DR   GeneID; 4017; -.
DR   KEGG; hsa:4017; -.
DR   UCSC; uc003xdh.2; human.
DR   CTD; 4017; -.
DR   DisGeNET; 4017; -.
DR   GeneCards; LOXL2; -.
DR   H-InvDB; HIX0007387; -.
DR   HGNC; HGNC:6666; LOXL2.
DR   HPA; CAB025848; -.
DR   HPA; HPA036257; -.
DR   HPA; HPA056542; -.
DR   MIM; 606663; gene.
DR   neXtProt; NX_Q9Y4K0; -.
DR   OpenTargets; ENSG00000134013; -.
DR   PharmGKB; PA30429; -.
DR   eggNOG; ENOG410IE2X; Eukaryota.
DR   eggNOG; ENOG410XSN1; LUCA.
DR   GeneTree; ENSGT00870000136394; -.
DR   HOGENOM; HOG000220841; -.
DR   HOVERGEN; HBG052336; -.
DR   InParanoid; Q9Y4K0; -.
DR   KO; K00280; -.
DR   OMA; HVVCGMF; -.
DR   OrthoDB; EOG091G02XD; -.
DR   PhylomeDB; Q9Y4K0; -.
DR   TreeFam; TF326061; -.
DR   BRENDA; 1.4.3.13; 2681.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-2243919; Crosslinking of collagen fibrils.
DR   ChiTaRS; LOXL2; human.
DR   GeneWiki; LOXL2; -.
DR   GenomeRNAi; 4017; -.
DR   PRO; PR:Q9Y4K0; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000134013; -.
DR   CleanEx; HS_LOXL2; -.
DR   ExpressionAtlas; Q9Y4K0; baseline and differential.
DR   Genevisible; Q9Y4K0; HS.
DR   GO; GO:0005604; C:basement membrane; ISS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:InterPro.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IEA:InterPro.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0070492; F:oligosaccharide binding; IDA:UniProtKB.
DR   GO; GO:0004720; F:protein-lysine 6-oxidase activity; IDA:UniProtKB.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0006464; P:cellular protein modification process; IDA:UniProtKB.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0016570; P:histone modification; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0018277; P:protein deamination; IDA:UniProtKB.
DR   GO; GO:0046688; P:response to copper ion; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.10.250.10; -; 2.
DR   InterPro; IPR001695; Lysyl_oxidase.
DR   InterPro; IPR019828; Lysyl_oxidase_CS.
DR   InterPro; IPR001190; SRCR.
DR   InterPro; IPR017448; SRCR-like_dom.
DR   Pfam; PF01186; Lysyl_oxidase; 1.
DR   Pfam; PF00530; SRCR; 4.
DR   PRINTS; PR00074; LYSYLOXIDASE.
DR   PRINTS; PR00258; SPERACTRCPTR.
DR   SMART; SM00202; SR; 4.
DR   SUPFAM; SSF56487; SSF56487; 4.
DR   PROSITE; PS00926; LYSYL_OXIDASE; 1.
DR   PROSITE; PS00420; SRCR_1; 2.
DR   PROSITE; PS50287; SRCR_2; 4.
PE   1: Evidence at protein level;
KW   Basement membrane; Chromatin regulator; Chromosome; Complete proteome;
KW   Copper; Disulfide bond; Extracellular matrix; Glycoprotein; LTQ;
KW   Metal-binding; Nucleus; Oxidoreductase; Polymorphism;
KW   Reference proteome; Repeat; Repressor; Secreted; Signal; TPQ;
KW   Transcription; Transcription regulation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    774       Lysyl oxidase homolog 2.
FT                                /FTId=PRO_0000018532.
FT   DOMAIN       58    159       SRCR 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00196}.
FT   DOMAIN      188    302       SRCR 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00196}.
FT   DOMAIN      326    425       SRCR 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00196}.
FT   DOMAIN      435    544       SRCR 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00196}.
FT   REGION      548    751       Lysyl-oxidase like.
FT   METAL       626    626       Copper. {ECO:0000255}.
FT   METAL       628    628       Copper. {ECO:0000255}.
FT   METAL       630    630       Copper. {ECO:0000255}.
FT   MOD_RES     689    689       2',4',5'-topaquinone.
FT                                {ECO:0000250|UniProtKB:P33072}.
FT   CARBOHYD    288    288       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    455    455       N-linked (GlcNAc...) (complex)
FT                                asparagine.
FT                                {ECO:0000269|PubMed:23319596}.
FT   CARBOHYD    644    644       N-linked (GlcNAc...) (complex)
FT                                asparagine.
FT                                {ECO:0000269|PubMed:23319596}.
FT   DISULFID     84    148       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID     97    158       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    128    138       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    218    291       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    231    301       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    265    275       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    351    414       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    364    424       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    395    405       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    464    530       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    477    543       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    511    521       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    573    579       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    625    673       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    657    663       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    685    695       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   DISULFID    732    746       {ECO:0000255|PROSITE-ProRule:PRU00196}.
FT   CROSSLNK    653    689       Lysine tyrosylquinone (Lys-Tyr).
FT                                {ECO:0000269|PubMed:23319596}.
FT   VARIANT     308    308       S -> R (in dbSNP:rs4871866).
FT                                /FTId=VAR_050009.
FT   VARIANT     359    359       S -> W (in dbSNP:rs4602894).
FT                                /FTId=VAR_050010.
FT   VARIANT     570    570       M -> L (in dbSNP:rs1063582).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_024527.
FT   MUTAGEN     455    455       N->Q: Inhibits secretion.
FT                                {ECO:0000269|PubMed:23319596}.
FT   MUTAGEN     626    628       HRH->ARA: Loss of catalytic activity and
FT                                abolishes ability to repress
FT                                transcription.
FT                                {ECO:0000269|PubMed:22483618}.
FT   MUTAGEN     644    644       N->Q: Inhibits secretion.
FT                                {ECO:0000269|PubMed:23319596}.
FT   MUTAGEN     689    689       Y->F: Does not affect ability to inhibit
FT                                keratinocyte differentiation.
FT                                {ECO:0000269|PubMed:22157764}.
FT   CONFLICT    184    184       E -> K (in Ref. 2; BAG35197).
FT                                {ECO:0000305}.
FT   CONFLICT    239    239       E -> G (in Ref. 3; BAD96197).
FT                                {ECO:0000305}.
FT   CONFLICT    295    295       L -> Q (in Ref. 6; AAD34343).
FT                                {ECO:0000305}.
FT   CONFLICT    536    536       Q -> R (in Ref. 2; BAG35197).
FT                                {ECO:0000305}.
FT   CONFLICT    652    652       H -> Q (in Ref. 6; AAD34343).
FT                                {ECO:0000305}.
FT   CONFLICT    746    746       C -> S (in Ref. 6; AAD34343).
FT                                {ECO:0000305}.
SQ   SEQUENCE   774 AA;  86725 MW;  9DF5D25D4824BCCD CRC64;
     MERPLCSHLC SCLAMLALLS PLSLAQYDSW PHYPEYFQQP APEYHQPQAP ANVAKIQLRL
     AGQKRKHSEG RVEVYYDGQW GTVCDDDFSI HAAHVVCREL GYVEAKSWTA SSSYGKGEGP
     IWLDNLHCTG NEATLAACTS NGWGVTDCKH TEDVGVVCSD KRIPGFKFDN SLINQIENLN
     IQVEDIRIRA ILSTYRKRTP VMEGYVEVKE GKTWKQICDK HWTAKNSRVV CGMFGFPGER
     TYNTKVYKMF ASRRKQRYWP FSMDCTGTEA HISSCKLGPQ VSLDPMKNVT CENGLPAVVS
     CVPGQVFSPD GPSRFRKAYK PEQPLVRLRG GAYIGEGRVE VLKNGEWGTV CDDKWDLVSA
     SVVCRELGFG SAKEAVTGSR LGQGIGPIHL NEIQCTGNEK SIIDCKFNAE SQGCNHEEDA
     GVRCNTPAMG LQKKLRLNGG RNPYEGRVEV LVERNGSLVW GMVCGQNWGI VEAMVVCRQL
     GLGFASNAFQ ETWYWHGDVN SNKVVMSGVK CSGTELSLAH CRHDGEDVAC PQGGVQYGAG
     VACSETAPDL VLNAEMVQQT TYLEDRPMFM LQCAMEENCL SASAAQTDPT TGYRRLLRFS
     SQIHNNGQSD FRPKNGRHAW IWHDCHRHYH SMEVFTHYDL LNLNGTKVAE GHKASFCLED
     TECEGDIQKN YECANFGDQG ITMGCWDMYR HDIDCQWVDI TDVPPGDYLF QVVINPNFEV
     AESDYSNNIM KCRSRYDGHR IWMYNCHIGG SFSEETEKKF EHFSGLLNNQ LSPQ
//
